Due to the unique physical characteristics of intervertebral disc degeneration (IVDD) and the pathological microenvironment that it creates, including inflammation and oxidative stress, effective self-repair is impossible. During the process of intervertebral disc degeneration, there is an increase in the infiltration of M1 macrophages and the secretion of proinflammatory cytokines. Here, we designed a novel injectable composite hydrogel scaffold: an oligo [poly (ethylene glycol) fumarate]/sodium methacrylate (OPF/SMA) hydrogel scaffold loaded with dual-drug/sustained-release PLGA microspheres containing IL-4 (IL-4-PLGA) and kartogenin (KGN-PLGA). This scaffold exhibited good mechanical properties and low immunogenicity while also promoting the sustained release of drugs. By virtue of the PLGA microspheres loaded with IL-4 (IL-4-PLGA), the composite hydrogel scaffold induced macrophages to transition from the M1 phenotype into the M2 phenotype during the early induced phase and simultaneously exhibited a continuous anti-inflammatory effect through the PLGA microspheres loaded with kartogenin (KGN-PLGA). Furthermore, we investigated the mechanisms underlying the immunomodulatory and anti-inflammatory effects of the composite hydrogel scaffold. We found that the scaffold promoted cell proliferation and improved cell viability in vitro. While ensuring mechanical strength, this composite hydrogel scaffold regulated the local inflammatory microenvironment and continuously repaired tissue in the nucleus pulposus via the sequential release of drugs in vivo. When degenerative intervertebral discs in a rat model were injected with the scaffold, there was an increase in the proportion of M2 macrophages in the inflammatory environment and higher expression levels of type II collagen and aggrecan; this was accompanied by reduced levels of MMP13 expression, thus exhibiting long-term anti-inflammatory effects. Our research provides a new strategy for promoting intervertebral disc tissue regeneration and a range of other inflammatory diseases.
1 December 2025 in Journal of Inflammation Research
Intervertebral disc degeneration (IVDD) is a major cause of low back pain and radicular pain, posing significant socio-economic challenges. The intervertebral disc is traditionally viewed as immune-privileged. This privilege is maintained by physical barriers and molecular factors such as Fas ligand. However, when these barriers are compromised, the nucleus pulposus (NP) can be exposed to the immune system. Recent evidence underscores a critical role for immune cells, particularly macrophages, in IVDD progression. This exposure can trigger an autoimmune response, leading to inflammation that aggravates dorsal root ganglion injury and results in hyperalgesia and pain. This review aims to autoimmunity, adaptive immunity, and the origins of pain in IVDD. We conclude that understanding these immune mechanisms is crucial, as they reveal promising avenues for future targeted immunotherapies.
Recent studies have provided links between glutamine metabolism and bone remodeling, but little is known about its role in primary osteoporosis progression. We aimed to determine the effects of inhibiting glutaminase (GLS) on two types of primary osteoporosis and elucidate the related metabolism. To address this issue, age-related and ovariectomy (OVX)-induced bone loss mouse models were used to study the in vivo effects of CB-839, a potent and selective GLS inhibitor, on bone mass and bone turnover. We also studied the metabolic profile changes related with aging and GLS inhibition in primary bone marrow stromal cells (BMSC) and that related with OVX and GLS inhibition in primary bone marrow-derived monocytes (BMM). Besides, we studied the possible metabolic processes mediating GLS blockade effects during aging-impaired osteogenic differentiation and RANKL-induced osteoclast differentiation respectively via in vitro rescue experiments. We found that inhibiting GLS via CB-839 prevented OVX-induced bone loss while aggravated age-related bone loss. Further investigations showed that effects of CB-839 treatment on bone mass were associated with alterations of bone turnover. Moreover, CB-839 treatment altered metabolic profile in different orientations between BMSC of aged mice and BMM of ovariectomized mice. In addition, rescue experiments revealed that different metabolic processes mediated glutaminase blockade effects between aging-impaired osteogenic differentiation and RANKL-induced osteoclast differentiation. Taken together, our data demonstrated the different outcomes caused by CB-839 treatment between two types of osteoporosis in mice, which were tightly connected to the suppressive effects on both aging-impaired osteoblastogenesis and OVX-enhanced osteoclastogenesis mediated by different metabolic processes downstream of glutaminolysis.
Intervertebral disc degeneration (IVDD), primarily driven by oxidative stress and inflammation, significantly impacts patient quality of life. Current ther
Intervertebral disc degeneration (IVDD) develops through interacting mechanical, matrix, nutritional, inflammatory and age-related processes. Mitochondrial reactive oxygen species (mtROS) and mitophagy participate in some of these contexts, but current evidence does not place mitophagy failure at the start of every degenerative trajectory. Most mechanistic studies have been performed in nucleus pulposus (NP) cells. In these models, mechanical overload, inflammatory mediators and oxidant stress can depolarize mitochondria, disturb fission–fusion balance and increase mtROS. Mitophagy can limit injury when damaged cargo is selected and delivered through a competent lysosomal pathway; accumulation of pathway markers during blocked flux, or mitochondrial clearance that is not matched by renewal, need not be protective. The most extensive mechanistic literature concerns apoptosis and senescence. Evidence linking mitochondrial quality control to pyroptosis and ferroptosis is growing but remains model-dependent, whereas direct evidence for necroptosis is comparatively sparse. We use a capacity-matching framework to organize these findings around damage burden, cargo selection, lysosomal completion and mitochondrial renewal within the regional metabolic constraints of the disc. This is an interpretive framework rather than a newly identified pathway. Its purpose is to define testable conditions under which mitophagy is likely to be protective, insufficient or maladaptive, while preserving the distinction between NP-derived evidence and the more limited evidence from annulus fibrosus and cartilage endplate cells.